Comparison
Noopept vs Semaglutide
Side-by-side of Noopept and Semaglutide. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Noopept
Noopept cognitive enhancer profile: 10 to 30 mg dosage, dipeptide nootropic mechanism, memory effects, and how it compares to piracetam.
Semaglutide
Semaglutide for weight loss: GLP-1 agonist (Ozempic, Wegovy) drives 15-17% mean loss at 2.4 mg/week in STEP trials. Watch lean-mass loss.
Effects at a glance
Noopept
- •Russian dipeptide nootropic developed in the 1990s, registered in Russia 2002 for cognitive impairment
- •Roughly 1,000-fold higher per-mg potency than piracetam; therapeutic dose 10 to 30 mg/day
- •Active metabolite cycloprolylglycine modulates AMPA receptors and increases NGF and BDNF in rodent hippocampus
- •Russian RCTs in stroke recovery and vascular cognitive impairment show modest improvements over 4 to 8 weeks
- •Western evidence base is essentially absent; healthy-adult enhancement trials have not been published
- •Unscheduled in the US but not approved for human consumption; UK is prescription-only since 2014
Semaglutide
- •Long-acting GLP-1 receptor agonist with a ~7-day half-life that supports once-weekly subcutaneous dosing
- •STEP trials reported ~15 to 17% mean body-weight loss at 2.4 mg/week over 68 weeks in adults with obesity
- •Lowers HbA1c by ~1.0 to 1.8 percentage points in type 2 diabetes versus placebo
- •SELECT trial showed reduced major cardiovascular events in adults with prior CVD and overweight or obesity
- •Up to 25 to 40% of weight lost can be lean mass; pairing with resistance training and protein intake mitigates this
- •GI effects (nausea, vomiting, constipation) drive most discontinuations and ease with slow titration
Side-by-side
| Attribute | Noopept | Semaglutide |
|---|---|---|
| Category | nootropic | pharmaceutical |
| Also known as | GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester, Omberacetam | Ozempic, Wegovy, Rybelsus |
| Half-life (hr) ↗ | 0.7 | 168 |
| Typical dose (mg) ↗ | 20 | 2.4 |
| Dosing frequency | 2 to 3 times daily, last dose before mid-afternoon | weekly (SC); daily (oral Rybelsus) |
| Routes | oral, sublingual | subcutaneous, oral |
| Onset (hr) | 0.5 | 24 |
| Peak (hr) | 1 | 72 |
| Molecular weight | 318.37 | 4113.58 |
| Molecular formula | C17H22N2O4 | - |
| Mechanism | Hydrolyzed to active metabolite cycloprolylglycine; AMPA receptor modulation, BDNF and NGF upregulation, antioxidant and antiexcitotoxic effects. | Long-acting GLP-1 receptor agonist; potentiates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic satiety centers. |
| Legal status | Approved in Russia and CIS states; prescription-only in UK; unscheduled and unapproved in US, EU varies | Prescription only (FDA-approved, EMA-approved) |
| WADA status | unknown | allowed |
| DEA / Rx | Not scheduled in the US | Rx only (not a controlled substance); FDA-approved for type 2 diabetes (2017) and chronic weight management (2021) |
| Pregnancy | Not recommended | Not recommended; discontinue 2 months before planned pregnancy |
| CAS | 157115-85-0 | 910463-68-2 |
| PubChem CID | 183503 | 56843331 |
| Wikidata | Q4321022 | Q27089394 |
Safety profile
Noopept
Common side effects
- headache
- irritability
- sleep disturbance with late-day dosing
- occasional blood pressure elevation
Contraindications
- pregnancy
- lactation
- pediatric use
- severe hepatic impairment
- severe renal impairment
Interactions
- memantine and other glutamatergic agents: theoretical AMPA-pathway interaction(minor)
- antidepressants: theoretical effect via BDNF axis, undocumented(minor)
- antihypertensives: occasional blood pressure elevation may require monitoring(minor)
Semaglutide
Common side effects
- nausea
- vomiting
- diarrhea
- constipation
- decreased appetite
- injection-site reactions
- fatigue
Contraindications
- personal or family history of medullary thyroid carcinoma
- multiple endocrine neoplasia type 2
- pregnancy
- history of pancreatitis (use caution)
Interactions
- insulin: additive hypoglycemia risk; insulin dose typically reduced(major)
- sulfonylureas (glipizide, glyburide): hypoglycemia risk, sulfonylurea dose often reduced(major)
- oral medications (general): delayed gastric emptying can alter absorption kinetics(moderate)
- warfarin: monitor INR due to altered absorption(moderate)
Which Should You Take?
Semaglutide comes out ahead for most readers on the criteria we weight: 2 catalogued goals, prescription-only, oral dosing, with a Tier-A outcome catalogued. Noopept is the right call when one of the conditionals below applies.
- → If your priority is focus or working memory, pick Noopept.
- → If your priority is memory, pick Noopept.
- → If your priority is metabolic health and glucose control, pick Semaglutide.
- → If your priority is fat loss, pick Semaglutide.
Edge case: Half-lives differ materially (Noopept ~0.7 hr vs Semaglutide ~168 hr). Semaglutide reaches steady state faster; Noopept is easier to dial in if tolerability is uncertain.
Default choice: Semaglutide. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Noopept only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Noopept and Semaglutide?
Noopept and Semaglutide differ in category (nootropic vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Noopept or Semaglutide?
Noopept half-life is 0.7 hours; Semaglutide half-life is 168 hours.
Can you stack Noopept with Semaglutide?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper